Samuel Goldhaber
Cardiovascular Disease · Boston, MANPI 1992795520
Payments from drug & device makers
Across 56 payments — averaging $2301.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$62K
- EKOS Corporation$50K
- Boehringer Ingelheim International GmbH$9K
- Agile Therapeutics, Inc.$7K
- Boehringer Ingelheim Canada Ltd.ltee$1K
What the payments were for
- Consulting fees$11,90071%
- Speaking & faculty fees$3,84023%
- Travel & lodging$9426%
- Food & beverage$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $61,600 |
| EKOS Corporation | 18 | $50,400 |
| Boehringer Ingelheim International GmbH | 5 | $8,740 |
| Agile Therapeutics, Inc. | 5 | $7,000 |
| Boehringer Ingelheim Canada Ltd.ltee | 6 | $1,137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,877 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 291 | $390,218 |
| XareltoRivaroxaban | 203 | $250,432 |
| JardianceEmpagliflozin | 138 | $142,799 |
| EntrestoSacubitril/Valsartan | 58 | $89,353 |
| Fondaparinux Sodium | 35 | $79,325 |
| OzempicSemaglutide | 43 | $47,457 |
| Repatha SureclickEvolocumab | 28 | $43,548 |
| Praluent PenAlirocumab | 46 | $41,622 |
| SavaysaEdoxaban Tosylate | 28 | $20,447 |
| TrulicityDulaglutide | 12 | $12,548 |
| Rosuvastatin Calcium | 284 | $9,707 |
| VascepaIcosapent Ethyl | 19 | $7,744 |
| Metoprolol Succinate | 266 | $6,088 |
| Ezetimibe | 112 | $5,798 |
| Ranolazine ErRanolazine | 33 | $5,730 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.